Although our results presented in Table S1 have to be interpreted with care because they are based on observations in a relatively small but consecutive group of AML/ALL patients and without a validation group, these observations suggest that serum levels of the p14 endocan fragment for untreated acute leukemia patients do not show a similar general increase and wide variation as observed for endocan [3] (Table S1; all p14 fragment results presented in this table have not been and will not be published elsewhere). The gene discussed is ESM1; the disease is acute lymphoblastic leukemia.